Saturday 17 October 2026
Export CURX’s income statement to Excel — free account
Curanex Pharmaceuticals Inc
CURX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 4,671.4% and free cash flow fell 272.3%, each against the same quarter a year earlier.
4.62
0.21
−4.35%
Follow CURX
Curanex Pharmaceuticals Inc (CURX) P/E ratio
Curanex Pharmaceuticals Inc has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| KPTI Karyopharm Therapeutics Inc. compare | n/m |
| APRE Aprea Therapeutics, Inc. compare | n/m |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| XCUR Exicure, Inc. compare | n/m |
| SNGX Soligenix Inc. compare | n/m |
| CALC CalciMedica Inc. compare | n/m |
| CURX Curanex Pharmaceuticals Inc | n/m |
| MBRX Moleculin Biotech, Inc. compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)